This site is intended for healthcare professionals
CSU Learning Zone
Declaration of sponsorship Novartis Pharma AG and J. Uriach y Compañía S.A

Industry-Sponsored eLearning

Declaration of sponsorship Novartis Pharma AG and J. Uriach y Compañía S.A
Read time: 160 mins
Last updated:29th Oct 2021
Published:29th Oct 2021

Put your knowledge of chronic spontaneous urticaria (CSU) to the test.

  • Explore a range of eLearning modules to improve your understanding of CSU
  • Familiarise yourself with the guidelines and learn more about the anti-IgE pathway
  • Consolidate your learning by taking part in our interactive quizzes

These eLearning modules have been developed by EPG Health for Medthority in collaboration with Novartis Pharma AG

Course overview

On completion of this module participants should have a good understanding of:

  • the role of mast cells and their mediators in CSU pathogenesis
  • the differences between type I and type IIb autoimmunity
  • the differences between the IgE receptors FcεRI and CD23
  • how anti-IgE therapies can be used to treat CSU
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Course overview

On completion of this module participants should have a good understanding of:

  • the humanistic and economic burden of CSU
  • current EACCI/GA2LEN/EDF/WAO guidelines for the management of CSU
  • the limitations of currently available therapies
  • the benefits of current and future anti-IgE therapies

Evaluation questions will be asked at the end of the module. You must achieve a score of 60% or above to pass.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Course overview

A World-wide Antihistamine-Refractory Chronic Urticaria Patient Evaluation (the AWARE study) offers insight into the disease burden, and real-world treatment patterns in patients with H1-antihistamine refractory chronic urticaria, under conditions of daily living.

On completion of this course, participants will understand:

  • The aims and objectives of the AWARE study
  • How real-world treatment patterns measure up against the treatment algorithm recommended in international guidelines
  • The burden of CSU and impact of angioedema on quality of life
  • Changes in patient-reported outcomes over the two-year study period
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

These eLearning modules have been developed by EPG Health for Medthority. This content has been developed in collaboration with Novartis Pharma AG. EPG Health received funding from Novartis Pharma AG in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. The views presented in the videos are those of the presenters and not necessarily those of the industry sponsor, Novartis Pharma AG. Any data on non- Novartis products are based on publicly available information at the time of content update. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country.

Welcome: